Intervention: Emtricitabine and tenofovir
Trial phase: Phase 4
SMILES: CC(C)OC(=O)OCOP(=O)(COC(C)Cn1cnc2c(N)ncnc21)OCOC(=O)OC(C)C.Nc1nc(=O)n(C2CSC(CO)O2)cc1F.O=C(O)C=CC(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 36
Group description: 12 healthy volunteers will dose with Truvada Pill and we will collect blood and hair over all three phases

Truvada Pill: Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weeklySubjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly

AEs reported for participants across all dose groups as there were none to report.
Eligibility criteria:
Inclusion Criteria

Healthy volunteer between the ages of 18 and 70, inclusive on the date of screening, with an intact gastrointestinal tract. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, and clinical laboratory tests
Recent medical history in good medical standing, without evidence of fever five days prior to enrollment
HIV-negative
Able to swallow pills
Has minimum hair required to provide study samples
Not allergic to any component of the study drug
Signed and dated informed consent indicating that they have been informed of all pertinent details of the trial and are willing to participate
Willing and able to comply with scheduled visits, laboratory tests and trial procedures
Willing to use at least one form of acceptable birth control throughout the duration of the study
Negative, or receiving treatment, for syphilis at screening
Hemoglobin Grade 2 or lower, with no clinically significant medical issues that would preclude blood sampling

Exclusion Criteria

Age outside of desired range
Confirmed positive results for HIV, Hepatitis B or C at screening
Subjects of all genders actively involved in the conception process, in addition to cisgender female subjects who are in the immediate post-partum period or breastfeeding
Insufficient amount of hair or unwilling to keep hair length at least 1 centimeter throughout duration of study
Unable or unwilling to comply with all lifestyle measures and/or visits
Impaired renal function, as documented by a creatinine clearance <80 mL/min with the Cockcroft-Gault equation
Has donated blood within the past 56 days in the amount greater than 500 mL
Has taken an investigational drug in the past 4 months
Clinical, laboratory, or surgical abnormalities that would preclude sample collection
Has a condition, which, in the opinion of the investigator, is likely to interfere with follow-up or ability to take the study medication appropriately
Any clinically significant laboratory result Grade 2 or greater according to the Division of AIDS (DAIDS) Laboratory Grading Tables
History of regular alcohol consumption exceeding 14 drinks (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of spirits) per week